← All Neumora Therapeutics, INC filings

Neumora Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NMRA
Neumora Therapeutics, INC
10-K: Neumora sets 2026 CNS catalysts; cash runway into 2027
Neumora outlined multiple 2026 readouts, detailed loan and ATM financing activity, and reported a $236.9M 2025 net loss with $182.5M in year-end cash as it advances MDD, Alzheimer’s agitation, schizophrenia and obesity programs.
NASDAQ
NMRA
Neumora Therapeutics, INC
10-K: Neumora Therapeutics Reports 2024 Financial Results, Provides Clinical Pipeline Update
Neumora Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical-stage neuroscience programs.
NASDAQ
NMRA
Neumora Therapeutics, INC
10-K: Neumora Therapeutics Reports on Pipeline Progress and Financials in Annual 10-K Filing
Neumora Therapeutics' annual 10-K filing details the company's clinical pipeline progress, financial status, and strategic direction in neuroscience drug development.